H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $102.00.
Joseph Pantginis has given his Buy rating due to a combination of factors including the promising potential of Viking Therapeutics’ VK2735, a dual GLP-1/GIP agonist. The drug is positioned well in the competitive landscape of GLP-1 therapies, particularly with its oral formulation, which has shown impressive results in early trials.
The Phase 1 study of oral VK2735 demonstrated significant weight loss and maintained a strong safety profile, differentiating it from other oral GLP-1 agonists. Pantginis believes that the upcoming data from the Phase 2 VENTURE-Oral trial could further enhance VK2735’s market position, supporting the Buy rating with a price target of $102.